- Poster presentation
- Open Access
In-vitro studies on the sensitivity pattern of Plasmodium falciparum to antimalarial drugs and local herbal extracts
© Olasehinde et al; licensee BioMed Central Ltd. 2012
- Published: 15 October 2012
- Malaria Parasite
- Plasmodium Falciparum
The resistance of human malaria parasites to antimalarial compounds has become of considerable concern, particularly in view of the shortage of novel classes of antimalarial drugs. One way to prevent resistance is by using new compounds that are not based on existing synthetic antimicrobial agents. Sensitivity of one hundred (100) P. falciparum isolates to chloroquine, quinine, amodiaquine, mefloquine, sulphadoxine/pyrimethamine, artemisinin, Momordica charantia (Ejirin,) Diospyros monbuttensis (Eegun eja) and Morinda lucida (Oruwo) was determined using the in-vitro microtest (Mark III) technique to determine the IC50 of the drugs. All the isolates tested were sensitive to Quinine, Mefloquine and Artesunate. Only 51% of the isolates were resistant to chloroquine, 13% to amodiaquine and 5% to sulphadoxine pyrimethamine respectively. Highest resistance to chloroquine (68.9%) was recorded among isolates from Yewa zone while highest resistance to amodiaquine (30%) was observed in Ijebu zone. Highest resistance to sulphadoxine and pyrimethamine was recorded in Yewa and Egba zones respectively. A significant positive correlation was observed between the responses to artemisinin and mefloquine (P=0.001), artemisinin and quinine (P=0.05), Quinine and mefloquine (P= 0.01). A significant negative correlation was observed between the responses to chloroquine and mefloquine (P=0.05). Highest antiplasmodial activity was obtained with the ethanolic extract of Diospyros monbuttensis (IC50 = 32 µg/ml) while the lowest was obtained from Morinda lucida (IC50 =250 µg/ml). Natural products isolated from plants used in traditional medicine, which have potent antiplasmodial action in vitro, represents potential sources of new antimalarial drugs.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.